Prostate cancer: endogenous chemical castration.

We report treatment of intermediate risk prostate cancer in a patient with a brief period of androgen deprivation secondary to a pituitary adenoma. This was a patient with intermediate risk prostate cancer diagnosed in the setting of an elevated prostate-specific antigen (PSA).

The patient subsequently demonstrated a decline in PSA along with symptoms of hypogonadism and visual disturbance, and was consequently found to have a pituitary tumour. Trans-sphenoidal resection of the sellar mass was performed with normalisation of hormone profiles. The patient subsequently completed a course of radiation therapy for prostate cancer with PSA nadir to undetectable levels without evidence of biochemical recurrence at 7 months follow-up.

BMJ case reports. 2016 Apr 28*** epublish ***

Olugbemisola Oredein McCoy, Michaella M Prasad, Natalie Singer

Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA., Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA., Department of Urology, Cincinnati VA Medical Center, Cincinnati, Ohio, USA.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe